Navigation Links
MiMedx Group Announces Third Quarter 2011 Results
Date:10/26/2011

KENNESAW, Ga., Oct. 26, 2011 /PRNewswire/ -- MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the third quarter and nine months ended September 30, 2011.

The Company recorded record revenue for the quarter of $2,152,000, a 12% percent increase over second quarter of 2011 revenue of $1,929,000 and nearly a twenty-fold increase over third quarter of 2010 revenue of $108,000. The Company recorded a net loss of $1,766,000, or $.02 per diluted common share, for the third quarter, a $738,000 improvement over the second quarter net loss of $2,504,000, or $.03 per diluted common share, and a $1,088,000 improvement as compared to a net loss of $2,854,000, or $.05 per diluted common share, in the third quarter of 2010. Earnings before interest, taxes, depreciation, amortization and share based compensation (Adjusted EBITDA*) for the third quarter of 2011 were a loss of $934,000, a $489,000 improvement as compared to the second quarter loss of $1,423,000 and a $1,306,000 improvement compared to a loss of $2,240,000 in the third quarter of 2010.

Revenue for the nine months ended September 30, 2011, was $5,125,000, as compared to revenue of $545,000 recorded for the nine months ended September 30, 2010. The Company reported a net loss of $7,617,000, or $0.11 per diluted common share, for the nine months ended September 30, 2011, as compared to a net loss of $8,693,000, or $0.15 per diluted common share, for the same nine month period in 2010. Adjusted EBITDA* for the nine months ended September 30, 2011, were a loss of $4,675,000, as compared to a loss of $6,425,000 in the same nine month period of 2010. The Company ended the quarter with $637,000 in cash and has a commitment for a $1.5 million line of credit to fund working capital growth due to the planned revenue ramp.

Manage
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MiMedx Groups EpiFix® Receives American Podiatric Medical Association Seal of Approval
2. MiMedx Group Partners With Affirmative Solutions
3. MiMedx Group Receives FDA Clearance to Market Its HydroFix™ Ortho Shield™ Device
4. MiMedx Announces Launch of AmnioFix™ Nerve Wrap
5. MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting
6. MiMedx Group, Inc. Announces Release Date for First Quarter Results
7. MiMedx Completes Acquisition of Surgical Biologics
8. MiMedx Receives Additional CE Certification for Its HydroFix™ Technology
9. MiMedx Announces Agreement to Acquire Surgical Biologics
10. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
11. MiMedx Group Announces Addition of Sales Director for Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013  Neuralstem, Inc. (NYSE MKT: CUR) today reported ... principal investigator, presented updated Phase I data from its ... the treatment of amyotrophic lateral sclerosis (ALS or ... diabetes special medical symposium in Bucharest, Romania ... Therapeutic Advances in Stem Cell Therapy," Dr. Feldman outlined ...
(Date:5/20/2013)... Mass. , May 20, 2013 ... and advisory firms for pharmaceutical and healthcare issues, ... that therapies offering a greater effect on quality ... unmet need. Given the high level of subjectivity ... of life, interviewed thought leaders state that it ...
(Date:5/19/2013)... Calif. , May 20, 2013  Whole-cell pertussis ... acellular pertussis vaccines during a large recent outbreak, according ... Whole-cell pertussis vaccines, also called DTwP, were ... with safety concerns that ultimately led to the development ... By the late 1990s, the United States ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4
... ST. LOUIS, Oct. 20 Stereotaxis, Inc. (Nasdaq: ... launched the Odyssey Interventional Network, a training and ... cardiovascular community.  The portal will showcase innovative electrophysiology ... centers around the world.  The Odyssey Interventional Network ...
... 20 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ... nine analyses relating to its LEVADEX™ orally inhaled ... FREEDOM-301 Phase 3 trial, at the 2010 European ... Nice, France.  EHMTIC is a biennial congress of ...
Cached Medicine Technology:Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training 2Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training 3Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training 4MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress 2MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress 3MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress 4
(Date:5/20/2013)... HealthDay Reporter , , MONDAY, May 20 (HealthDay News) -- ... are twice as likely to become obese adults as ... young, a new 30-year study shows. Researchers found ... higher body-mass index (BMI) and obesity, even if they ... no difference; well-off or poor, they tended toward ...
(Date:5/20/2013)... 2013 In celebration of National Women’s ... accomplishments achieved at The Feinstein Institute for Medical ... Advancing Women in Science and Medicine (AWSM) , ... Scientists, educators, business and community leaders from the ... of women in science. , “Women face unique ...
(Date:5/20/2013)... ANN ARBOR, Mich. As high schoolers prepare for ... a "study drug" -- a prescription stimulant or amphetamine ... University of Michigan poll shows only one in 100 ... teen has used a study drug., Study drugs refer ... attention deficit hyperactivity disorder (ADHD); commonly prescribed medicines in ...
(Date:5/20/2013)... Join Seva Foundation in celebrating its 35th Anniversary with ... Fine Arts Theater in San Francisco, featuring: Snatam ... with host Wavy Gravy. All proceeds will benefit Seva Foundation’s ... seats are $40 & $55, VIP tickets are $150 and ... row seat at the show. Tickets are available through ...
(Date:5/20/2013)... A new Benefits of Pharmacy Home Delivery ... of the MedEx Pack announced. The new ... Delivery, in order to provide useful details for those who ... Clyde Furuta, MedEx Direct owner and pharmacist said, “One of ... a product like the MedEx Pack, patients can receive their ...
Breaking Medicine News(10 mins):Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 3Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2Health News:Memorial Day Kirtan Concert Palace of Fine Arts Theater in San Francisco Featuring: Snatam Kaur, Jai Uttal, C.C. White & Shimshai with host Wavy Gravy,May 27th 7:00 PM 2Health News:Benefits of Pharmacy Home Delivery Report Published by MedEx Direct 2
... study finds , , FRIDAY, March 14 (HealthDay News) -- Higher ... harm older men, U.S. research shows. , A ... followed 1,000 seniors in three Florida retirement communities for up ... levels of anxiety at the start of the study lived ...
... Gottsch to Visit Washington, D.C., and Meet with Elected ... Boise,Idaho, will travel to Washington, D.C., this April 1 ... restoration of the,Americans with Disabilities Act, support for epilepsy ... epilepsy., Gottsch, 9, is one of 50 young ...
... Peter Serwik to Visit Washington, D.C., and Meet with ... of,Middletown, Del. will travel to Washington, D.C., this April ... for restoration of the,Americans with Disabilities Act, support for ... for epilepsy., Serwik, 7, is one of 50 ...
... C.J. Soeby to Visit Washington, D.C., and Meet With ... of Buckeye,Ariz. will travel to Washington, D.C., this April ... for restoration of the,Americans with Disabilities Act, support for ... for epilepsy., Soeby, 10, is one of 50 ...
... Washington, D.C., and Meet with Elected,Officials, WASHINGTON, March ... Washington, D.C., this April 1 to meet,with congressional leaders ... Disabilities Act, support for epilepsy public health,programs and more ... is one of 50 young people with epilepsy participating ...
... Washington, D.C., and Meet with Elected,Officials, WASHINGTON, March ... to Washington, D.C., this April 1 to meet,with congressional ... with Disabilities Act, support for epilepsy public health,programs and ... 16, is one of 50 young people with epilepsy ...
Cached Medicine News:Health News:Anxiety Helps Elderly Women Live Longer 2Health News:Idaho Youth Named National Epilepsy Spokesperson 2Health News:Delaware Youth Named National Epilepsy Spokesperson 2Health News:Arizona Youth Named National Epilepsy Spokesperson 2Health News:Vermont Youth Named National Epilepsy Spokesperson 2Health News:Virginia Youth Named National Epilepsy Spokesperson 2
... produce Type III, laboratory-grade pure water at ... directly with potable tap water and combine ... design that is easy to operate, reliable, ... produced at a low operating cost., Applications, ...
... systems produce Type III, laboratory-grade pure water ... fed directly with potable tap water and ... system design that is easy to operate, ... water produced at a low operating cost., ...
... chest freezer, with over 23 cu. ft. ... boxes. Built to the same standards as ... a cost-saving alternative. Rust-resistant, powder coated exterior; ... four adjustable shelves. Keyed lock and 4-digit ...
... Advanced Series CO2 Incubators by ... Microprocessor achieves precise temperature and ... evaporation & RH% is displayed ... and RH are displayed digiton ...
Medicine Products: